Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III , Active‐Controlled Study
Primary result · Percent weight change from baselineResult — go to the resultLeast-squares mean difference 0.26 % 95% CI −0.86% to 1.39%Authors' conclusion
Test synthetic semaglutide was found to be non-inferior to Reference semaglutide in weight management with or without comorbidities.
Study context
- Population
- Adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with ≥1 weight-related comorbidity (hypertension, dyslipidemia or T2D), 21 centers in India246 completed
- Participants
- 270 adults
- Comparison
- Test semaglutide vs Reference semaglutide once weekly
- Testn = 177
- Referencen = 90reference
- Primary endpoint
- Percentage change in bodyweight from baseline
- Follow-up
- Week 24
Methodological detailsphase III, non-inferiority, active-controlled, multicentre (21 centers in India)
- Phase III
- Non-inferiority
- Active-controlled
- Multicentre (21 centers in India)
Primary result
Percent weight change from baseline
Least-squares mean difference
0.26 %
95% CI −0.86% to 1.39%
Change by group
Test
−13.8
mean · SD 4.28% · %
Reference
−14.1
mean · SD 4.11% · %
Testvs Reference
least-squares mean difference 0.26 % (95% CI −0.86% to 1.39%)
As reported in the abstract
Further findings
≥5% weight loss · Week 24
≥10% weight loss · Week 24
BMI, waist circumference, SF-36 total score and glycemic parameters
- Improvements comparable between groups
Safety
Treatment-emergent adverse events
Treatment-emergent adverse events
- Gastrointestinal events most common
Original publication
Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III , Active‐Controlled Study. Diabetes Obes Metab. Published 6 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →